Buscar resultados de ensayos clínicos
Muckle-Wells Syndrome - 14 Studies Found
Estado | Estudiar |
Completed |
Nombre del estudio: Efficacy, Safety, and Tolerability of ACZ885 in Patients With Muckle-Wells Syndrome Condición: Muckle Wells Syndrome Fecha: 2007-04-25 Intervenciones:
|
Completed |
Nombre del estudio: Safety and Tolerability of Rilonacept in Muckle-Wells Syndrome (MWS) or Schnitzler Syndrome (SchS) Condición:
Fecha: 2010-01-07 Intervenciones: Drug: rilonacept 160mg of rilonacept 1x/week Other N |
Withdrawn |
Nombre del estudio: A Pilot Study of XOMA 052 in Familial Cold Autoinflammatory Syndrome / Muckle-Wells Syndrome and Behcet's Disease Condición:
Intervenciones: Drug: Canakinumab (ACZ885) 6 mL glass vial containing 150 mg lyophilized Canakinumab reconstituted with |
Completed |
Nombre del estudio: Efficacy, Safety and Tolerability of ACZ885 in Pediatric Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease Condición:
Intervenciones: Drug: ACZ885 |
Completed |
Nombre del estudio: Efficacy and Safety Study of Canakinumab Administered for 6 Months (24 Weeks) in Japanese Patients With Cryopyrin-associated Periodic Syndromes Followed by an Extension Phase Condición:
Intervenciones: Drug: canakinumab canakinumab |
Completed |
Nombre del estudio: The CAP-2 Trial: Effect of Direct Pulp Capping Versus Partial Pulpotomy Condición: Dental Pulp Exposure Fecha: 2005-09-13 Intervenciones:
|
Active, not recruiting |
Nombre del estudio: Continued Access to PREVAIL (CAP2) Condición: Atrial Fibrillation Fecha: 2012-11-06 Intervenciones: Device: WATCHMAN LAA Closure Technology |
Completed |
Nombre del estudio: Rilonacept for Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS) Condición:
|
Completed |
Nombre del estudio: Safety, Efficacy, Pharmacokinetics, Pharmacodynamics of ACZ885 in Patients With NALP3 Mutations and Clinical Symptoms Condición: NALP3 Mutation Fecha: 2007-06-18 Intervenciones: Drug: canakinumab |